ActivX Expands Strategic Collaboration Agreement With Pfizer

Pfizer and ActivX Biosciences, a wholly owned subsidiary of Tokyo-based Kyorin Pharmaceutical, have entered into a strategic collaborative agreement encompassing multiple projects ranging from discovery to developmental stage programs across multiple research sites of Pfizer's Global Research and Development organization. Under the terms of the agreement, ActivX will apply its novel chemical technologies and high-throughput protein analysis to a number of Pfizer programs spanning drug discovery, proteomic profiling, compound selectivity and biological activity, and mechanisms of toxicity.

BioSpace (http://www.biospace.com/news_story.cfm?StoryID=18991520&full=1)